RxDoctor Payments Data

Codi Ehrlich, MD

Family Medicine · Dodge City, KSNPI 1316442130

Payments from drug & device makers

$2,516in general payments, 2019–2025

Across 135 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$618
  • Novo Nordisk$401
  • Lilly USA, LLC$349
  • AbbVie$242
  • Pfizer$181
  • Sumitomo Pharma America, Inc.$112
  • plus $615 from 15 others

What the payments were for

  • Food & beverage$2,516100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,516 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$1,726
Medicare patients
47
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol23$29,491
RybelsusSemaglutide11$19,927
OzempicSemaglutide11$10,480
JardianceEmpagliflozin14$10,452
Incruse ElliptaUmeclidinium Bromide18$8,680
Breo ElliptaFluticasone/Vilanterol15$8,629
LinzessLinaclotide14$6,951
JentaduetoLinagliptin/Metformin Hcl11$5,707
EliquisApixaban14$5,326
Rosuvastatin Calcium32$2,156
Dexlansoprazole DrDexlansoprazole13$1,891
Tolterodine Tartrate13$1,400
Gabapentin45$715
Losartan Potassium56$707
Celecoxib12$574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$401$30,40722 claims
AstraZenecaFarxiga$618$29,49123 claims
GSKIncruse Ellipta, Breo Ellipta$45$17,30933 claims
Boehringer IngelheimJardiance, Jentadueto$18$16,15925 claims
AbbVieLinzess$242$6,95114 claims
PfizerEliquis$181$5,32614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Dodge City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →